Special Supplement, March 2021

View Special Supplement, March 2021

The Era of IL-23: Introduction of Tildrakizumab
Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review
Tildrakizumab in Patients with Metabolic Syndrome: A Novel Approach

Published: 2021-03-01

Full Issue

Articles

The Era of IL-23: Introduction of Tildrakizumab

Melinda Gooderham, MSc, MD, FRCPC

2
- PDF (en)
- PDF (fr)
Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review

Alim R. Devani, MD, FRCPC, Vimal H. Prajapati, MD, FRCPC

3–8
- PDF (en)
- PDF (fr)
Tildrakizumab in patients with metabolic syndrome: A novel approach

Parbeer Grewal, MD

9–11
- PDF (en)
- PDF (fr)